Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Anderson, Rebecca ^a,b   Franch, Angels ^b   Castell, Margarida ^b   Perez Cano, Francisco J ^b   Bräuer, Rolf ^a   Pohlers, Dirk ^a   Gajda, Mieczyslaw ^a   Siskos, Alexandros P ^c   Katsila, Theodora ^c   Tamvakopoulos, Constantin ^c   Rauchhaus, Una ^d   Panzner, Steffen ^d   Kinne, Raimund W ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d Novosom AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOSOME; CYTOKINE; DEXAMETHASONE; DEXAMETHASONE 21-PHOSPHATE; DRUG CARRIER; DRUG DERIVATIVE; GLUCOCORTICOID; IMMUNOGLOBULIN G;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; ENCAPSULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; LEUKOCYTE COUNT; LIPOSOMAL DELIVERY; LIVER; MASS SPECTROMETRY; NONHUMAN; PERITONEUM MACROPHAGE; RAT; SPLEEN; SYNOVIUM; ANIMAL; ARTHRITIS; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEWIS RAT; LYMPHOCYTE; METABOLISM; PATHOLOGY; SOLUBILITY; TISSUE DISTRIBUTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; GLUCOCORTICOIDS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; LIPOSOMES; LYMPHOCYTES; MACROPHAGES, PERITONEAL; RATS; RATS, INBRED LEW; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 77954671356     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3089     Document Type: Article

References (51)

1. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990, 144:3347-3353.
2. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996, 39:115-124. 10.1002/art.1780390116, 8546720.
3. Kinne RW, Stuhlmüller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther 2007, 9:224. 10.1186/ar2333, 2246244, 18177511.
4. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum 1997, 40:639-647. 10.1002/art.1780400408, 9125245.
5. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999, 26:717-719.
6. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801. 10.1126/science.1281554, 1281554.
7. Scott BB, Weisbrot LM, Greenwood JD, Bogoch ER, Paige CJ, Keystone EC. Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis Rheum 1997, 40:490-498. 10.1002/art.1780400315, 9082937.
8. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus methotrexat in patients with early rheumatoid arthritis: two year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450. 10.1002/art.10308, 12115173.
9. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1999, 130:478-486.
10. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473-488. 10.1038/nrd1109, 12776222.
11. Anderson P, Louie J, Lau A, Broder M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005, 7:3-9. 10.1007/s11926-005-0002-2, 15760575.
12. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005, 34:19-22. 10.1016/j.semarthrit.2005.01.005, 15852250.
13. Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003, 112:37-53.
14. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2757-2764. 10.1002/art.22056, 16947774.
15. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of RA: 2002 Update. Arthritis Rheum 2002, 46:328-346. 10.1002/art.10148, 11840435, American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
16. Bijlsma JW, van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci 2002, 966:82-90. 10.1111/j.1749-6632.2002.tb04205.x, 12114262.
17. Da Silva JA, Bijlsma JW. Optimizing glucocorticoid therapy in rheumatoid arthritis. Rheum Dis Clin North Am 2000, 26:859-880. 10.1016/S0889-857X(05)70173-3, 11084948.
18. Hong KS, Hack JK, Hyun PK, Lee HJ, Byun SM. Liposomes with anti-inflammatory steroid prednisolone palmitate. Drug Dev 1988, 14:765-777.
19. Rauchhaus U, Kinne RW, Pohlers D, Wiegand S, Wölfert A, Gajda M, Bräuer R, Panzner S. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann Rheum Dis 2009, 68:1933-1934. 10.1136/ard.2009.108985, 19910302.
20. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003, 48:2059-2066. 10.1002/art.11140, 12847701.
21. Metselaar JM, van den Berg WB, Holthuysen AE, Wauben MH, Storm G, van Lent PL. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 2004, 63:348-353. 10.1136/ard.2003.009944, 1754935, 15020326.
22. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003, 126:1895-1904. 10.1093/brain/awg176, 12805101.
23. Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y. Amphipathic weak acid glucocorticoid prodrugs remote loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum 2008, 58:119-129. 10.1002/art.23230, 18163482.
24. Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, van Der Meer JWM, Cortens FHM, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 2000, 292:1071-1079.
25. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006, 112:15-25. 10.1016/j.jconrel.2006.01.005, 16515818.
26. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007, 122:349-355. 10.1016/j.jconrel.2007.05.015, 17610982.
27. MacLachlan I, Cullis P. Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles. Adv Genet 2005, 53:157-188. full_text, 16240993.
28. Pohlers D, Schmidt-Weber CB, Franch A, Kuhlmann J, Bräuer R, Emmrich F, Kinne RW. Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-κB binding activity and TNF-α secretion of T cells. Arthritis Res 2002, 4:184-189. 10.1186/ar404, 111020, 12010568.
29. Lasch J, Weissig V, Brandl M. Preparation of Liposomes. Liposomes: A Practical Approach 2002, 3-30. Oxford: Oxford University Press, Torchilin VP, Weissig V.
30. Van Veldhofen PP, Mannaerts GP. Inorganic and organic phosphate measurements in the nanomolar range. Anal Biochem 1987, 161:45-48. 10.1016/0003-2697(87)90649-X, 3578786.
31. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res 1970, 31:125-150. 10.1016/S0022-5320(70)90150-4, 5442603.
32. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992, 267:18759-18765.
33. Pelegrí C, Castell M, Serra M, Rabanal M, Rodríguez-Palmero M, Castellote C, Franch A. Prevention of adjuvant arthritis by the W3/25 anti-CD4 monoclonal antibody is associated with a decrease of blood CD4+CD45RChigh T cells. Clin Exp Immunol 2001, 125:470-477. 10.1046/j.1365-2249.2001.01592.x, 1906151, 11531956.
34. Pohlers D, Nissler K, Frey O, Simon J, Petrow PK, Kinne RW. Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation. Clin Exp Immunol 2004, 135:409-415. 10.1111/j.1365-2249.2003.02381.x, 1808984, 15008972.
35. Tamvakopoulos CS, Neugebauer JM, Donnelly M, Griffin PR. Analysis of betamethasone in rat plasma using automated solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry. Determination of plasma concentrations in rat following oral and intravenous administration. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 776:161-168. 10.1016/S1570-0232(02)00271-4, 12137997.
36. Damonte G, Salis A, Rossi L, Magnani M, Benatti U. High throughput HPLC-ESI-MS method for the quantitation of dexamethasone in blood plasma. J Pharm Biomed Anal 2007, 43:376-380. 10.1016/j.jpba.2006.06.042, 16887316.
37. Barrera P, Mulder S, Smetsers AI, Storm G, Beijnen JH, Metselaar JM, van Riel PL. Long-circulating Liposomal Prednisolone versus Pulse Intramuscular Methylprednisolone in Patients with Active Rheumatoid Arthritis [abstract]. Proceedings of the American College for Rheumatology 2008 Annual Scientific Meeting 24-29 June 2008 in San Francisco L10.
38. Rauchhaus U, Schwaiger FW, Panzner S. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res Ther 2009, 11:R190. 10.1186/ar2889, 20003498.
39. Tetlow LC, Lees M, Ogata Y, Nagase H, Woolley DE. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int 1993, 13:53-59. 10.1007/BF00307734, 8356391.
40. Schmidt-Weber CB, Pohlers D, Siegling A, Schädlich H, Buchner E, Volk HD, Palombo-Kinne E, Emmrich F, Kinne RW. Cytokine gene activation in synovial membrane, regional lymph nodes, and spleen during the course of rat adjuvant arthritis. Cell Immunol 1999, 195:53-65. 10.1006/cimm.1999.1509, 10433797.
41. Hochhaus G, Barth J, al-Fayoumi S, Suarez S, Derendorf H, Hochhaus R, Mollmann H. Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). J Clin Pharmacol 2001, 41:425-434. 10.1177/00912700122010285, 11304899.
42. Schmidt-Weber CB, Rittig M, Buchner E, Hauser I, Schmidt I, Palombo-Kinne E, Emmrich F, Kinne RW. Apoptotic cell death in activated monocytes following incorporation of clodronate-containing liposomes. J Leukoc Biol 1996, 60:230-244.
43. Cher DJ, Mossmann TR. Two types of murine helper T cell clone. II. Delayed type hypersensitivity is mediated by Th1 clones. J Immunol 1987, 138:3688-3694.
44. Moser DM. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212. 10.1189/jlb.0602325, 12554797.
45. Yang X. Distinct function of Th1 and Th2 type delayed type hypersensitivity: protective and pathological reactions to chlamydial infection. Microsc Res Tech 2001, 53:273-277. 10.1002/jemt.1093, 11340672.
46. Schmidt-Weber CB, Kinne RW, Voll R, Emmrich F, Buchner E. Experimentelle Anti-Makrophagen-Therapie. Update: Clinical Immunology, Vol. 5 Arthritiden, Therapeutische Perspektiven 1997, 408-431. Lengerich, Berlin, Düsseldorf, Riga, Scottsdale; Arizona, Wien, Zagreb: Pabst Science Publishers, Sack U.
47. Elliott P, Peters RF, White AM. A study of the relationship between glucocorticoid-induced weight loss in rats and the activity of skeletal-muscle and cardiac-muscle ribosomes in vitro. Biochem J 1971, 125:106P-107P. 1178322, 5144222.
48. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997, 54:30-45. 10.2165/00003495-199700544-00007, 9361959.
49. Szebeni J. Complement activation related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit Rev Ther Drug Carrier Syst 2001, 18:567-606.
50. Metselaar JM, Sanders S, van Lamoen R, vam Bloois L, Laverman P, Baranyi L, Savay S, Milosevits J, Wauben MHM, Alving CR, Storm G, Szebeni J. Complement activation-related hypersensitivity reactions caused by pegylated liposomes. PhD Thesis 2002, Chapter 8:124-135. Dept. of Pharmaceutics, Institute of Pharmaceutical Science. Utrecht University, Netherlands.
51. Morito T, Oishi K, Yamamoto M, Matsumoto K. Biphasic regulation of Fc-receptor mediated phagocytosis of rabbit alveolar macrophages by surfactant phospholipids. Tohoku J Exp Med 2000, 190:15-22. 10.1620/tjem.190.15, 10750736.